The value of serology testing to manage SARS-CoV-2 infections

Laia Fernández-Barat; Ruben López-Aladid; Antoni Torres

doi:10.1183/13993003.02411-2020

The value of serology testing to manage SARS-CoV-2 infections

Eur Respir J. 2020 Aug 27;56(2):2002411. doi: 10.1183/13993003.02411-2020. Print 2020 Aug.

Authors

Laia Fernández-Barat^{1

2

3}, Ruben López-Aladid^{1

2

3}, Antoni Torres^{4

2

3}

Affiliations

¹ Cellex Laboratory, CibeRes (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, 06/06/0028), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
² School of Medicine, University of Barcelona, Barcelona, Spain.
³ Dept of Pneumology, Thorax Institute, Hospital Clinic of Barcelona, Barcelona, Spain.
⁴ Cellex Laboratory, CibeRes (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, 06/06/0028), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain atorres@clinic.cat.

Abstract

Validated serology tests are a good complement for the SARS-CoV-2 RNA test, allow rapid epidemiological control and reveal immune status before and after vaccination. https://bit.ly/3eKAc6h

Publication types

Editorial
Comment

MeSH terms

Betacoronavirus*
COVID-19
Coronavirus Infections / epidemiology*
Humans
Pandemics*
Pneumonia, Viral / epidemiology*
SARS-CoV-2